title: Follicular fluid concentrations of IGF-I, IGF-II, IGFBP-3, VEGF, AMH, and inhibin-B in women undergoing controlled ovarian hyperstimulation using GnRH agonist or GnRH antagonist.
abstract: OBJECTIVE
  To compare follicular fluid concentrations of IGF-I, IGF-II, IGFBP-3, inhibin-B, VEGF, and AMH in women undergoing controlled ovarian hyperstimulation with a long-luteal GnRH agonist protocol or multiple-dose GnRH antagonist protocol.
  
  
  METHODS
  A total of 80 cycles were included; long-luteal GnRH agonist group (n=40) and multiple dose GnRH antagonist group (n=40). All follicular fluid samples were obtained from mature follicles during oocyte retrieval. IGF-I and IGFBP-3 concentrations were measured by immunoradiometric assay. IGF-II, VEGF, AMH, and inhibin-B concentrations were measured by enzyme-linked immunosorbent assay.
  
  
  RESULTS
  There were no significant differences in the concentrations of the studied follicular fluid markers, cycle parameters, and treatment outcomes between GnRH agonist and GnRH antagonist protocols.
  
  
  CONCLUSIONS
  The long-luteal GnRH agonist protocol and multiple-dose GnRH antagonist protocol seem to have similar effects on the follicular microenvironment in women undergoing controlled ovarian hyperstimulation.
authors: Ankara University School of Medicine, Department of Obstetrics and Gynecology, 06100 Ankara, Turkey.
authors: Aysenur
authors: A
authors: Kaya
authors: Cem S
authors: CS
authors: Atabekoglu
authors: Korhan
authors: K
authors: Kahraman
authors: Salih
authors: S
authors: Taskin
authors: Batuhan
authors: B
authors: Ozmen
authors: Bulent
authors: B
authors: Berker
authors: Murat
authors: M
authors: Sonmezer
mesh_terms: D000328:Adult; D054304:Anti-Mullerian Hormone / Q000378:metabolism; D015415:Biomarkers / Q000378:metabolism; D005260:Female; D005300:Fertility Agents, Female / Q000494:pharmacology*; D015571:Follicular Fluid / Q000378:metabolism*; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists* / Q000037:antagonists & inhibitors*; D006801:Humans; D007246:Infertility / Q000378:metabolism / Q000628:therapy; D007247:Infertility, Female / Q000378:metabolism / Q000628:therapy*; D007265:Inhibins / Q000378:metabolism; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000378:metabolism; D050498:Live Birth; D006080:Ovarian Follicle / Q000187:drug effects* / Q000378:metabolism; D010062:Ovulation Induction / Q000379:methods*; D011247:Pregnancy; D018873:Pregnancy Rate; D013002:Somatomedins / Q000378:metabolism; D013810:Therapeutic Equivalency; D014421:Turkey / Q000453:epidemiology; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism; D055815:Young Adult
chemical_list: D015415:Biomarkers; D005300:Fertility Agents, Female; C515497:IGFBP3 protein, human; D018972:Insulin-Like Growth Factor Binding Protein 3; D013002:Somatomedins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C422364:inhibin B; D007987:Gonadotropin-Releasing Hormone; D007265:Inhibins; D054304:Anti-Mullerian Hormone